Shanghai Fosun Pharmaceutical Stock Price To Earning
| SFOSFDelisted Stock | USD 1.70 0.00 0.00% |
Shanghai Fosun Pharmaceutical fundamentals help investors to digest information that contributes to Shanghai Fosun's financial success or failures. It also enables traders to predict the movement of Shanghai Pink Sheet. The fundamental analysis module provides a way to measure Shanghai Fosun's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Shanghai Fosun pink sheet.
Shanghai |
Shanghai Fosun Pharmaceutical Company Price To Earning Analysis
Shanghai Fosun's Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.
Current Shanghai Fosun Price To Earning | 13.80 X |
Most of Shanghai Fosun's fundamental indicators, such as Price To Earning, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Shanghai Fosun Pharmaceutical is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Generally speaking, the Price to Earnings ratio gives investors an idea of what the market is willing to pay for the company's current earnings.
CompetitionBased on the latest financial disclosure, Shanghai Fosun Pharmaceutical has a Price To Earning of 13.8 times. This is 46.59% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The price to earning for all United States stocks is 51.95% higher than that of the company.
Shanghai Price To Earning Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Shanghai Fosun's direct or indirect competition against its Price To Earning to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Shanghai Fosun could also be used in its relative valuation, which is a method of valuing Shanghai Fosun by comparing valuation metrics of similar companies.Shanghai Fosun is currently under evaluation in price to earning category among its peers.
Shanghai Fundamentals
| Return On Equity | 0.0756 | |||
| Return On Asset | 0.0204 | |||
| Profit Margin | 0.08 % | |||
| Operating Margin | 0.07 % | |||
| Current Valuation | 15.52 B | |||
| Shares Outstanding | 551.94 M | |||
| Shares Owned By Insiders | 0.07 % | |||
| Shares Owned By Institutions | 35.60 % | |||
| Price To Earning | 13.80 X | |||
| Price To Book | 1.45 X | |||
| Price To Sales | 0.31 X | |||
| Revenue | 39.01 B | |||
| Gross Profit | 18.71 B | |||
| EBITDA | 8.71 B | |||
| Net Income | 4.74 B | |||
| Cash And Equivalents | 14.64 B | |||
| Cash Per Share | 5.49 X | |||
| Total Debt | 9.05 B | |||
| Debt To Equity | 0.64 % | |||
| Current Ratio | 1.00 X | |||
| Book Value Per Share | 16.30 X | |||
| Cash Flow From Operations | 3.95 B | |||
| Earnings Per Share | 0.21 X | |||
| Number Of Employees | 36.28 K | |||
| Beta | 0.76 | |||
| Market Capitalization | 12.25 B | |||
| Total Asset | 93.29 B | |||
| Retained Earnings | 10.37 B | |||
| Working Capital | (817 M) | |||
| Current Asset | 10.27 B | |||
| Current Liabilities | 11.09 B | |||
| Z Score | 0.6 | |||
| Annual Yield | 0.03 % | |||
| Net Asset | 93.29 B | |||
| Last Dividend Paid | 0.56 |
About Shanghai Fosun Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Shanghai Fosun Pharmaceutical's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Shanghai Fosun using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Shanghai Fosun Pharmaceutical based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. You can also try the Stocks Directory module to find actively traded stocks across global markets.
Other Consideration for investing in Shanghai Pink Sheet
If you are still planning to invest in Shanghai Fosun Pharm check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Shanghai Fosun's history and understand the potential risks before investing.
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine |